Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceutical’s (RCE) flagship anti-infective UTI treatment R327 was proven to be safe last week
- The company’s phase I/II trial is now accelerating ahead of schedule with the help of NSW-based partner Scientia
- Recce expects data read-outs from the next stage of the trial process to be delivered before the end of the year
- The company is using larger dosages infused via IV at faster rates after phase I data showed a safe drug with no known side effects or complications
- Recce is up 1.10 per cent, trading at 68.8 cents at 3:45 pm AEST
Recce Pharmaceuticals (RCE) has announced it’s ahead of schedule in its latest human patient trials for the Recce 327 anti-infective, R327.
R327 is designed to disrupt the existing treatment market for urinary tract infections (UTIs).
R327 is a serum that is injected via IV by medical professionals to destroy bacteria that cause UTIs. Recent results have shown the product to be safe to use, effective, and superior in its efficacy compared to competitor products.
In short, R327’s active ingredients collect in the urine without any complication for the recipient and destroy dangerous bacteria in the space of hours.
Today, the company confirmed its NSW-based trial partner Scientia Clinical Research has moved ahead with the first doses for participants in the phase I/II R327 trial.
The remaining subjects will all be dosed by the end of this week. The phase I/II trial sees patients dosed with faster infusion rates than those administered in phase I, now that the company has confirmed the safety profile of R327.
Both male and female patients are being administered with faster infusions. Patients in the phase I/II trial will receive 2500mg via IV injection.
The company expects data read-outs from phase I/II before the end of the year.
Recce was 1.10 per cent, trading at 68.8 cents at 3:45 pm AEST.
